MarketPeel
Insider Trading Intelligence
Pricing
…
SP

Stuart Poulton

KPTI
EVP, CHIEF DEVELOPMENT OFFICER · KARYOPHARM THERAPEUTICS INC. · CIK 0001942597
FILING MIX · LIFETIME41%/59%
BUYS
11
SELLS
16
TOTAL VALUE
$145.4K
COMPANIES
1
ACTIVE SINCE
Feb 2023
HOLDINGS NOW
94,821
AVG SELL PX
$2.60
TRADE KIND
SHOWING 27 / 27
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
15 backtested trades · 8 horizons · 13 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Stuart Poulton, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d15+73.33%-2.39%-1.40%-0.99%-7.45%—
14d15+80.00%-7.22%-1.51%-5.71%-8.32%—
30d15+66.67%-1.77%-1.77%-0.00%-1.67%—
60d15+66.67%-1.62%+0.04%-1.67%-11.27%—
90d15+86.67%-17.84%+2.47%-21.21%-22.39%—
180d15(2 pending)+76.92%-25.25%+8.50%-33.75%-44.63%—
1y15(4 pending)+90.91%-44.30%+20.16%-64.46%-75.58%—
2y15(7 pending)+100.00%-67.16%+43.25%-110.41%-110.23%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
KPTI · 94,821 shares · as of May 14, 2026
087,994175,989263,983351,977202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 11 buys / 16 sellsCOVERAGE · 14 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE
EVP, Chief Development Officer
403$9.50$3.8K94,821May 14, 2026May 15, 2026 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
896——95,224May 13, 2026May 15, 2026 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE
EVP, Chief Development Officer
5,101$9.41$48.0K94,328Mar 2, 2026Mar 3, 2026 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE
EVP, Chief Development Officer
378$8.63$3.3K99,429Feb 17, 2026Feb 19, 2026 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
32,415——99,807Jan 31, 2026Feb 3, 2026 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
39,682——67,392Oct 15, 2025Oct 16, 2025 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE
EVP, Chief Development Officer
401$6.43$2.6K27,710Sep 15, 2025Sep 16, 2025 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
888——28,111Sep 12, 2025Sep 16, 2025 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE
EVP, Chief Development Officer
191$4.37$83527,223Jul 29, 2025Jul 30, 2025 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE
EVP, Chief Development Officer
3,548$6.29$22.3K27,414Mar 4, 2025Mar 6, 2025 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
9,166——9,166Feb 28, 2025Mar 4, 2025 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
4,583——30,962Feb 28, 2025Mar 4, 2025 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
5,000——26,379Feb 28, 2025Mar 4, 2025 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
10,000——10,000Feb 28, 2025Mar 4, 2025 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE
EVP, Chief Development Officer
5,914$0.63$3.7K320,714Feb 18, 2025Feb 19, 2025 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE
EVP, Chief Development Officer
2,883$1.06$3.1K326,628Jul 30, 2024Jul 31, 2024 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE
EVP, Chief Development Officer
6,155$1.20$7.4K329,511Mar 1, 2024Mar 4, 2024 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE
EVP, Chief Development Officer
16,311$1.17$19.1K335,666Feb 29, 2024Mar 4, 2024 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
188,205——351,977Feb 28, 2024Feb 29, 2024 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE
EVP, Chief Development Officer
5,748$1.33$7.6K163,871Feb 15, 2024Feb 20, 2024 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE
EVP, Chief Development Officer
99$1.40$139163,772Feb 15, 2024Feb 20, 2024 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
13,333——169,619Jan 24, 2024Jan 25, 2024 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
2,845$1.70$4.8K156,286Jul 28, 2023Aug 1, 2023 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
95,000——159,131Feb 28, 2023Mar 2, 2023 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE
EVP, Chief Development Officer
5,665$3.19$18.1K64,335Feb 15, 2023Feb 17, 2023 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE
EVP, Chief Development Officer
196$3.16$61964,131Feb 15, 2023Feb 17, 2023 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE
EVP, Chief Development Officer
8$3.23$2664,327Feb 15, 2023Feb 17, 2023 ↗View →
Other insiders · KPTI
Loading peer insiders…
About this filer
CIK 0001942597
ROLE
EVP, Chief Development Officer
PRIMARY
KPTI
COMPANIES
1
ACTIVE SINCE
Feb 2023
MARKETPEEL · /INSIDER/0001942597DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback